Treatment
Combination therapy clinical trials
We’re tracking 879 recruiting studies that include Combination therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT06241326Recruiting
Immunotherapy for liver cancer study
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
Nanjing, JiangsuAges 18 years+ - NCT06482801RecruitingPhase 2
Immunotherapy combo for newly treated liver cancer
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
GuangzhouAges 18–75 - NCT06483347RecruitingPhase 2
Immunotherapy combo for inoperable lung cancer
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07805551RecruitingPhase 1/Phase 2
HDM2017 combination therapy for advanced colorectal cancer
This study tests a new drug called HDM2017 in combination with other treatments for advanced colorectal cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07788456RecruitingPhase 4
Sequential combination therapy for newly diagnosed ITP in adults
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
TianjinAges 18–75 - NCT07784296Recruiting
Triple combination therapy for high blood pressure in Korean adults
This study tests a three-drug combination pill for high blood pressure in Korean adults. It aims to see if this treatment is safe and effective.
Gyeonggi-doAges Any age - NCT06546111RecruitingPhase 1/Phase 2
Diosmin and hesperidin for H. pylori infection
This trial tests whether a combination of two natural plant compounds, diosmin and hesperidin, can safely and effectively treat Helicobacter pylori (H. pylori) infection in people who have not been treated for it before. The goal is to see if this therapy offers a new option for clearing the bacteria.
Shibīn al KawmAges 18–75 - NCT07766187RecruitingPhase 2
Durvalumab and focused ultrasound for liver cancer after chemo
This trial tests combining two treatments: durvalumab (an immunotherapy drug) and histotripsy (a focused ultrasound that breaks down tumor tissue) for people with a type of liver cancer called intrahepatic cholangiocarcinoma. It aims to see if adding histotripsy after initial chemotherapy helps control the cancer better.
Madison, WisconsinAges 18 years+ - NCT07759895RecruitingPhase 2
Two-drug treatment for negative symptoms of schizophrenia
This trial tests two medicines, deferiprone and N-acetylcysteine, taken together to see if they improve negative symptoms of schizophrenia, such as lack of motivation or pleasure. It aims to find a new option for people who still have these symptoms despite their current antipsychotic treatment.
JerusalemAges 18–40 - NCT07722884Recruiting
Tamsulosin alone or with tadalafil for enlarged prostate symptoms
This study tests whether taking tadalafil (at 2.5 mg or 5 mg) along with tamsulosin is better for treating urinary symptoms caused by an enlarged prostate than taking tamsulosin alone. It aims to find the best dose combination to improve your quality of life.
Cairo, Cairo GovernorateAges 45 years+ - NCT06538012RecruitingPhase 1/Phase 2
Tumor immune cells plus pembrolizumab for advanced lung cancer
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Beijing, Beijing MunicipalityAges 16–90 - NCT07714668RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07699380RecruitingPhase 2
Metabolic therapy to improve insulin sensitivity in type 1 diabetes
This trial tests a drug that may help your body use insulin better and improve how your cells produce energy. It might lead to better blood sugar control and less insulin needed.
Seattle, WashingtonAges 18–69 - NCT06649162Recruiting
Fatty liver risk in type 2 diabetes and new combo therapy
This study is looking at how often people with type 2 diabetes also have fatty liver disease, and whether a new combination medication (dapagliflozin and pioglitazone) can help manage both conditions.
Andong, Gyeongsangbuk-doAges 19 years+ - NCT06640582RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced brain cancer
This trial tests a new treatment for advanced brain cancers like glioma and meningioma. It combines your own immune cells (tumor-infiltrating lymphocytes or TILs) with an immunotherapy drug (pembrolizumab) to help your body fight the tumor. It's for people who have tried other treatments without success or have no standard options left.
Beijing, Beijing MunicipalityAges 16–90 - NCT06411600RecruitingPhase 2
Combination therapy for BRAF-mutated colorectal cancer
This trial tests a combination of targeted therapies for people with metastatic colorectal cancer that has a specific BRAF V600E mutation and has progressed after initial treatment. The goal is to see if this combination can shrink tumors or stop them from growing further.
BarcelonaAges 18 years+ - NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT06532812RecruitingPhase 1/Phase 2
TIL therapy plus immunotherapy for advanced breast cancer
This trial tests a personalized therapy using your own immune cells (TILs) combined with immunotherapy to fight advanced breast cancer that has not responded to other treatments. It may help if you have a tumor that can be biopsied and you are generally healthy enough for the procedures.
Beijing, Beijing MunicipalityAges 16–90 - NCT06683885RecruitingPhase 1/Phase 2
Targeted drug combo for elderly DLBCL patients
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
Zhengzhou, HenanAges 65 years+ - NCT07645222RecruitingPhase 1
Testing HS-20122 combined therapy for advanced lung cancer
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
Guangzhou, GuangdongAges 18–75 - NCT06557369Recruiting
New light therapy for intermediate age-related macular degeneration
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
BergamoAges 50 years+ - NCT07622186RecruitingPhase 2
SKB571 combination therapy for advanced lung cancer
This trial tests a new drug called SKB571, given in combination with other treatments, for non-small cell lung cancer (a common type of lung cancer). The study aims to see if this combination helps shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT06698965RecruitingPhase 2
Study of trilaciclib, envafolimab, etoposide, and carboplatin for extensive-stage small cell lung cancer
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07610616Recruiting
Testing ADC Drug Effectiveness Using Lung Cancer Lab Models
This research study tests how a lung cancer drug called Trastuzumab deruxtecan (T-DXd) works by growing your cancer cells in a lab dish and studying them with your immune cells. The goal is to better understand which patients might benefit most from this treatment.
Guangzhou, GuangdongAges 18–100
Common questions
- Are there clinical trials studying Combination therapy?
- Yes. Clin2 currently lists 879 recruiting studies that include Combination therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Combination therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Combination therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Combination therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.